VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents
NCT01655589 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 74
Last updated 2012-08-02
Summary
The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.
Conditions
- Macular Degeneration
Sponsors & Collaborators
-
Institute of Vision, Brasil
lead OTHER
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-01-31
Countries
- Brazil
Study Locations
More Related Trials
-
Single or Combined Protocols for NV-AMD
NCT03552770 ·Status: COMPLETED ·Phase: PHASE4
-
Visual Outcome After Vitrectomy With Subretinal tPA Injection
NCT05196139 ·Status: COMPLETED
-
Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
NCT04138420 ·Status: COMPLETED
-
Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
NCT01327222 ·Status: COMPLETED ·Phase: PHASE3
-
Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
NCT01350323 ·Status: COMPLETED ·Phase: NA
-
Bevacizumab for Neovascular Age-related Macular Degeneration
NCT01306591 ·Status: COMPLETED ·Phase: NA
-
Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration
NCT01032109 ·Status: COMPLETED ·Phase: NA
-
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00556348 ·Status: COMPLETED ·Phase: PHASE4
-
Combination Therapy for Neovascular Age Related Macular Degeneration
NCT00447031 ·Status: WITHDRAWN ·Phase: NA
-
An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects
NCT00709449 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
NCT01256580 ·Status: WITHDRAWN ·Phase: NA
-
VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
NCT00727753 ·Status: COMPLETED
-
Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy
NCT00423059 ·Status: COMPLETED ·Phase: NA
-
Intravitreal Bevacizumab for Age-Related Macular Degeneration
NCT00347165 ·Status: TERMINATED ·Phase: PHASE2
-
Intravitreal Bevacizumab for Diabetic Retinopathy
NCT00600262 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD
NCT00684853 ·Status: UNKNOWN ·Phase: PHASE2
-
Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment
NCT02287298 ·Status: COMPLETED
-
Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
NCT00347399 ·Status: TERMINATED ·Phase: PHASE2
-
Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD
NCT03744806 ·Status: COMPLETED
-
Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia
NCT00967850 ·Status: COMPLETED ·Phase: PHASE3
-
Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD
NCT00370370 ·Status: UNKNOWN ·Phase: PHASE3
-
Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia
NCT01716026 ·Status: COMPLETED ·Phase: PHASE3
-
Targeted Fluorescence Imaging in AMD
NCT05262244 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
NCT00503022 ·Status: COMPLETED ·Phase: PHASE1
-
Bevacizumab Intravitreal for Myopic Choroidal Neovascularization
NCT00797992 ·Status: COMPLETED ·Phase: PHASE4